Pharma Journalist -

Hoffmann-La Roche Limited (Roche Canada) announced that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA  IV (tocilizumab for…
Read More...

Digital health’s deployment has been as fast as it has wide. Over the past 18 months it has become the central focus for health systems, health plans as well as solution providers…
Read More...

BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration…
Read More...

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of…
Read More...

Liminatus Pharma LLC (“Liminatus”), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp (“Iris”), a publicly traded…
Read More...

iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with…
Read More...

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the…
Read More...

Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic…
Read More...

argenx SE announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of…
Read More...

Kintara Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of…
Read More...